AbstractReference Products and WHO International Standards/Reference Reagents have roles to play in the development and characterization of similar biological products (SBPs). However, these roles are distinct and non-interchangeable. The uses of these materials and their limitations are considered in this paper
Kobuszewski Bartosz. Biological medicinal products: reference and biosimilar products – selected iss...
Regulatory guidance documents clearly outline the requirements for demonstrating analytical comparab...
When the patent of a brand-name, marketed drug expires, new, generic products are usually offered. S...
AbstractReference Products and WHO International Standards/Reference Reagents have roles to play in ...
AbstractThe WHO guidelines on evaluating biosimilar products represent an important step forward in ...
AbstractThe WHO guidelines on evaluating similar biotherapeutic products (SBPs) were adopted by the ...
Biosimilars are biological medicinal products marketed as a copy of an originator (reference) produc...
What is a “non-comparable biotherapeutic product”? For the purposes of this paper, we will use the t...
AbstractThe expiration of patents on many biological medicinal products has prompted the development...
The World Health Organization (WHO) guidelines on evaluation of similar biotherapeutic products (SBP...
Biosimilars are biological medicinal products marketed as a copy of an originator (reference) produc...
2010[1], twenty two Countries and regions including EU and FDA have established their guidelines or ...
AbstractThe availability of biotherapeutic products to patients has a major impact on the success in...
To date, no consensus exists among stakeholders about the safety of switching between reference biol...
Many of the best-selling ‘blockbuster’ biological medicinal products are, or will soon be, facing co...
Kobuszewski Bartosz. Biological medicinal products: reference and biosimilar products – selected iss...
Regulatory guidance documents clearly outline the requirements for demonstrating analytical comparab...
When the patent of a brand-name, marketed drug expires, new, generic products are usually offered. S...
AbstractReference Products and WHO International Standards/Reference Reagents have roles to play in ...
AbstractThe WHO guidelines on evaluating biosimilar products represent an important step forward in ...
AbstractThe WHO guidelines on evaluating similar biotherapeutic products (SBPs) were adopted by the ...
Biosimilars are biological medicinal products marketed as a copy of an originator (reference) produc...
What is a “non-comparable biotherapeutic product”? For the purposes of this paper, we will use the t...
AbstractThe expiration of patents on many biological medicinal products has prompted the development...
The World Health Organization (WHO) guidelines on evaluation of similar biotherapeutic products (SBP...
Biosimilars are biological medicinal products marketed as a copy of an originator (reference) produc...
2010[1], twenty two Countries and regions including EU and FDA have established their guidelines or ...
AbstractThe availability of biotherapeutic products to patients has a major impact on the success in...
To date, no consensus exists among stakeholders about the safety of switching between reference biol...
Many of the best-selling ‘blockbuster’ biological medicinal products are, or will soon be, facing co...
Kobuszewski Bartosz. Biological medicinal products: reference and biosimilar products – selected iss...
Regulatory guidance documents clearly outline the requirements for demonstrating analytical comparab...
When the patent of a brand-name, marketed drug expires, new, generic products are usually offered. S...